Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.45 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12933065 | 1.00 | SLC6A1 (0.45) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL13179816 | 1.00 | SLC6A1 (0.45) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL14071147 | 0.86 | HRH3 (0.40) | SLC6A1SLC6A11SLC6A13HRH4HRH3 | |
| SCHEMBL9917291 | 0.86 | HRH3 (0.40) | SLC6A1SLC6A11SLC6A13HRH4HRH3 | |
| SCHEMBL14646583 | 0.86 | HRH3 (0.40) | SLC6A1SLC6A11SLC6A13HRH4HRH3 | |
| SCHEMBL4762513 | 0.84 | THRA (0.38) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL24915154 | 0.84 | SLC6A1 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL11915915 | 0.84 | HRH3 (0.35) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL12044420 | 0.82 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL18799769 | 0.82 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116348455-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090318491-A1 | Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders | YALE UNIVERISTY (US) | 2009-12-24 | — | — | US | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | SLC6A1 3063/4885GABRA5 4011/4885GABRB2 4168/4885 |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | SLC6A1 4791/4885GABRA5 4525/4885GABRB2 4838/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | SLC6A1 2706/4885GABRA5 4061/4885GABRB2 4175/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | SLC6A1 3049/4885GABRA5 3301/4885GABRB2 3707/4885 |
| US-20100009963-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | SLC6A1 2405/4885GABRA5 2055/4885GABRB2 1779/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | SLC6A1 3049/4885GABRA5 3301/4885GABRB2 3707/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | SLC6A1 4111/4885GABRA5 1584/4885GABRB2 3263/4885 |
| US-20090318491-A1 | Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders | CHRNA1, CHRNA5, CHRNA10 | SLC6A1 888/4885GABRA5 130/4885GABRB2 250/4885 |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | IDO1, IDO2, AADAC | SLC6A1 99/4885GABRA5 415/4885GABRB2 495/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | SLC6A1 4134/4885GABRA5 4200/4885GABRB2 4142/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | SLC6A1 2963/4885GABRA5 3862/4885GABRB2 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.